Efficacy of Atorvastatin as Adjunctive Treatment for Chronic Plaque Type Psoriasis
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This study aimed to assess the efficacy and safety of atorvastatin 40 mg/day as an adjunct to
betamethasone valerate 0.1% ointment applied twice daily in the treatment of patients with
mild to moderate chronic plaque type psoriasis, as determined by mean reduction in PASI
scores. Specific objectives included the determination and comparison of the absolute number
and proportion of patients who achieved PASI-50 and the mean reductions in lipid profile
(total cholesterol, HDL, LDL, triglycerides) and high-sensitivity C-reactive protein (hsCRP)
measured from baseline and every month thereafter up to 6 months of treatment. This study
also investigated the impact of atorvastatin treatment on the patients' quality of life as
well as the association of clinical response to the lipid-lowering and anti-inflammatory
effects of atorvastatin.